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Abstract
Background: Epidemiological studies suggest that smokeless tobacco in the form of Swedish snus has been used
by many smokers in Scandinavia to quit smoking, but the efficacy of snus has so far not been evaluated in
controlled clinical trials.
Methods: We conducted a randomized, double-blind, placebo-controlled, clinical trial aimed at assessing the
efficacy of snus to help adult cigarette smokers in Serbia to substantially reduce, and, eventually, completely stop
smoking. The study enrolled 319 healthy smokers aged 20-65 years at two occupational health centers in Belgrade,
Serbia. Most of them (81%) expressed an interest to quit rather than just reduce their smoking. Study products
were used ad libitum throughout the 48-week study period. The main study objective during the first 24 weeks
was smoking reduction. The primary end-point was defined as a biologically verified reduction of ≥ 50% in the
average number of smoked cigarettes per day during week 21-24 compared to baseline. During week 25-48
participants were actively instructed to stop smoking completely. Outcome measures of biologically verified,
complete smoking cessation included 1-week point prevalence rates at clinical visits after 12, 24, 36, and 48 weeks,
as well as 4-, 12- and 24-week continued cessation rates at the week 36 and 48 visits.
Results: At the week 24 visit, the proportion of participants who achieved the protocol definition of a ≥ 50%
smoking reduction was similar in the two treatment groups. However, the proportion that reported more extreme
reductions (≥ 75%) was statistically significantly higher in the snus group than in the placebo group (p < 0.01). The
results for biologically verified complete cessation suggested that participants in the snus group were more likely
to quit smoking completely than the controls; the odds ratio (snus versus placebo) for the protocol estimates of
cessation varied between 1.9 to 3.4, but these ratios were of borderline significance with p-values ranging from
0.04-0.10. Snus was well tolerated and only 2/158 (1.3%) participants in the snus group discontinued treatment due
to an adverse event (in both cases unrelated to snus).
Conclusions: Swedish snus could promote smoking cessation among smokers in Serbia, that is, in a cultural
setting without traditional use of oral, smokeless tobacco.
Trial registration: www.clinicaltrials.gov, identifier: NCT00601042
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The smoking prevalence is substantially higher in Cen-
tral and East European countries than in West Europe
[1]. In Serbia, for instance, smoking prevalence among
b o t hm a l e sa n df e m a l e si sr e p o r t e da t3 0 - 4 0 %[ 2 ] .D u r -
ing recent years, Serbian public health authorities have
initiated antismoking campaigns but the funding for
such activities is limited, as well as for modern, pharma-
ceutical smoking cessation pro d u c t s .P r o g r e s si sa l s o
hampered by the relatively low public awareness of the
health hazards associated with smoking.
Sweden demonstrates a unique pattern in terms of smok-
ing-related disease; male smoking-related deaths are radi-
cally fewer than in other European countries, and Sweden
i sa l s ot h eo n l yE Uc o u n t r yw h ere male smoking prevalence
is lower than among females [3]. During recent decades
smoking among Swedish males has decreased to a larger
extent than among women, probably related to the preva-
lent use in men of snus, a traditional Swedish oral tobacco
product, as a smoking cessation aid and replacement for
cigarettes [4]. The use of low-nitrosamine smokeless
tobacco of the Swedish type is associated with health risks
that are only a fraction of those caused by smoking [5-7].
Use of nicotine replacement may promote smoking
cessation as evidenced by numerous controlled clinical
trials on the role of pharmaceutical nicotine products
[8]. However, the cost of suchp r o d u c t si sp r o h i b i t i v e l y
high for most Serbian smokers. Swedish snus offers
another possibility for nicotine replacement. The Swed-
ish experience provides strong indirect support to the
notion that snus can promote smoking cessation and
help to reduce tobacco related disease [9-12]. Snus is
also generally regarded as less harmful than other smo-
keless tobacco products [13].
In contrast to Scandinavia, Serbia has no tradition of
oral, smokeless tobacco. Therefore, a pilot study was
conducted in Belgrade during 2004-2005 where 21 smo-
kers tested different Swedish snus products. The main
objective was to assess the acceptability of snus in a Ser-
bian setting. A marked reduction of average carbon
monoxide levels in exhaled air at the end of the one
month test period indicated a substantial reduction of
the number of cigarettes smoked. The study also
demonstrated that, if properly flavored, an oral moist
tobacco product like Swedish snus may be acceptable to
both male and female Serbian smokers.
Recruitment to a smoking cessation program may be
more successful if the proposed goal is to reduce smok-
ing rather than total cessation. Smokers who have made
previous unsuccessful quit attempts might abstain from
participating in a program if the requirement is immedi-
ate, total abstention. Initial smoking reduction may facil-
itate complete cessation later on [14].
These circumstances constituted the rationale for the
randomized trial presented here. The study aimed at
assessing the efficacy of a traditional Swedish low nitro-
samine smokeless tobacco product (snus) to help adult
cigarette smokers in Serbia to substantially reduce their
smoking and, eventually, completely stop smoking.
Methods
Study design
This study was an investigator-initiated, randomized,
multi-center, double-blind, parallel-group, placebo-con-
trolled, phase 4 clinical trial. It focused on the potential
of Swedish snus to reduce smoking and increase quit
rates among cigarette smokers motivated to reduce their
smoking or quit completely. The study was conducted
in compliance with the ethical principles of the Declara-
tion of Helsinki and the International Conference on
Harmonization Good Clinical Practice Guidelines (ICH-
GCP) at two occupational health care centers in Bel-
grade, Serbia during January 2008 through March 2010
[15]. The study was approved by the centers’ institu-
tional review board, and all participants provided written
informed consent prior to entering the study. Before
initiation, the study was registered on http://www.clini-
caltrials.gov (identifier: NCT00601042).
Study population
Participants were recruited through posters and other
printed material distributed at or in the vicinity of the
study sites, and by word-of-mouth. The two sites were
occupational health centers located at the head office
of a large Serbian corporation (NIS-Jugopetrol) and at
a major research institution in Belgrade (VinčaI n s t i -
tute of Nuclear Sciences). The inclusion criteria were:
age between 20 through 65 years, history of daily
smoking for more than one year, an average daily con-
sumption of more than 10 cigarettes during the past
month, motivation to substantially reduce or quit
smoking, good general health, and acceptance not to
take pharmaceutical nicotine products or any other
non-protocol treatment to facilitate smoking cessation
during the study period. Exclusion criteria were:
uncontrolled hypertension (systolic > 140 mg Hg, dia-
stolic > 90 mg Hg), history of coronary heart disease,
other significant heart condition, or any medical condi-
tion that may interfere with study procedures, preg-
nancy or nursing, current abuse of alcohol or illicit
drugs, current active oral disease that may interfere
with use of study product, significant current psychia-
tric disease or psychosocial problems that may inter-
fere with study procedures, and use of pharmaceutical
or other products for smoking reduction or cessation
within the past 3 months.
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The products were manufactured by Swedish Match AB
according to the GothiaTek
® standard [16] and were
supplied in identical, food-grade, plastic containers. The
products came in sachets (pouches) that were placed in
the anterior part of mouth between the upper gingiva
and cheek for 30-60 minutes. The participants could
choose from two different sachet sizes (0.5 g and 1 g)
and two different flavors (liquorice and eucalyptus).
Swedish snus according to the GothiaTek
® standard is a
low nitrosamine, moist, oral tobacco product with a
water content of c. 45-55%, a nicotine content of c. 1%,
and a pH of c. 8.5. The nicotine uptake from snus
sachets in comparison with a 2 mg nicotine polacrilex
gum was described previously [17]. Snus was found to
provide a more rapid uptake than the gum. However,
t h en i c o t i n eu p t a k ef r o ms m o k e dp r o d u c t ss u c ha s
cigarettes is much more rapid than with oral tobacco
due to the pulmonary mode of delivery [18].
The placebo snus products were almost identical to
the snus products in physical appearance, mouth feel,
pH, flavoring, and other sensory characteristics but they
did not contain tobacco or nicotine.
Interventions
With stratification by center, and using a block size of
six, a predefined, central, computer-generated randomi-
zation sequence assigned participants in a 1:1 ratio to
receive snus or matching placebo. Randomization was
done by consecutively associating each included partici-
pant’s identifiers with a unique, computer-generated
sequential number. Lists at the study sites linked these
numbers to specific study products, that is, snus or pla-
cebo. At the sites all study products were identified
solely by identification numbers which ensured that
both participants and investigators were blinded to
treatment assignments. The protocol did not include
procedures to assess the success of the blinding.
Each participant was sched u l e dt ob ef o l l o w e df o ra
total of 48 weeks. Study products were distributed to
the participants during the entire study period. Partici-
pants were instructed to cut down on smoking as much
as possible or quit smoking completely. Whenever they
felt an urge to smoke, they were instructed to take a
sachet of their allocated product. The number of sachets
consumed per day was determined by the participants
themselves. There was no prescribed tapering of product
usage. Unblinding of treatment assignments was not
done until after a participant had concluded the entire
48 week study period. Those who wanted to continue
with snus after 48 weeks were obliged to buy commer-
cially available products.
None of the study centers had previous experience
with smoking cessation interventions (as quit smoking
programs were non-existent in Serbia at the time of the
trial) or smokeless tobacco (as there is no traditional
use of such products in Serbia). However, the trialists
attended training sessions prior to the initiation of the
study which covered alternative approaches to smoking
cessation, the chemical composition of snus, the epide-
miology of snus use in Sweden, health effects of nicotine
and snus versus cigarette smoking, how to use the study
products, the need for adequate nicotine dosing to sup-
press cravings, methods for counseling of smokers who
want to quit, and proper use of study equipment.
Potential participants were invited to seminars during
which information was provided about health risks asso-
ciated with smoking and available smoking cessation
strategies. The physiological effects of nicotine were out-
lined, and an account given of the Swedish experience
with snus including potential health risks associated
with smokeless tobacco products. A few days-weeks
after a seminar, those interested to participate were
invited to a baseline visit during which their eligibility
was determined and written informed consent to partici-
pate was obtained. All included participants were pro-
vided with their allocated study product at the baseline
visit.
During the first 24 weeks the main study objective was
to substantially reduce smoking so the participants were
instructed to replace as many cigarettes as possible with
their allocated study product or quit completely. They
were informed that complete cessation should be the
ultimate goal but that smoking reduction could be an
important first step toward that aim. Information was
given that one 1.0 g sachet used according to the
instructions roughly should be able to replace one cigar-
ette. All participants were encouraged to remain in the
trial, attend all visits, and complete all assessments irre-
spective of study product usage or intensity of smoking.
The participants were instructed to document on a
weekly basis in a diary how many cigarettes they
smoked on average per day, and how many study pro-
ducts they had used. Those who managed to achieve the
protocol definition of a substantial smoking reduction at
the week 24 visit or who had quit completely (see
“Study end-points”), continued in the trial up to 48
weeks. During week 25-48 they were actively instructed
to quit smoking completely. Participants who did not
meet the protocol criteria for smoking reduction at the
week 24 visit were counted as treatment failures in all
efficacy analyses and were not actively followed after
week 24.
Clinical visits
The baseline visit was followed by 9 clinical visits over a
total of 48 weeks. Participants were also contacted by
telephone on two occasions (after 1 and 9 weeks). Each
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a check of the participant’s diary information, assess-
ment of adverse events, and brief counseling (< 5-10
minutes).
Assessments
T h ea s s e s s m e n ta tt h eb a s e l i n ev i s i ti n c l u d e dm e d i c a l
history, history of smoking including previous quit
attempts, measurements of height and weight, blood
pressure, CO in exhaled air (Bedfont Micro Smokerly-
zer, Sittingbourne, U.K.), assessment of nicotine depen-
dence with the Fagerström Test for Nicotine
Dependence (FTND) [19], pulmonary function tests
(EasyOne Spirometer, ndd Medical Technologies, Zur-
ich, Switzerland), and blood samples to assess the fol-
lowing biomarkers: total leukocytes (S-WBC), C-reactive
protein (S-CRP), total S-cholesterol, high density lipo-
protein (S-HDL), low density lipoprotein (S-LDL), S-
fibrinogen, and S-cotinine.
Follow-up clinical visits were scheduled after week 2,
6, 12, 18, 24, 30, 36, 42, and 48. They included assess-
ment of CO in exhaled air, self-reported smoking status
and study product usage based on the participant’s diary
information, adverse events, and blood pressure. The
pulmonary function tests, blood tests and measurement
of weight were repeated at four of these visits (week 12,
24, 36, and 48). The FTND was administered at two fol-
low up visits (week 24 and 48). The results were only
considered relevant for those who reported continued
smoking.
The telephone contacts scheduled after 1 and 9 weeks
included assessment of self-reported smoking status,
study product usage, and adverse events.
Study end-points
The primary end-point was smoking reduction at 24
weeks defined as a self-reported reduction of ≥ 50% in
the average number of smoked cigarettes per day during
week 21-24 compared to baseline, verified by a reduced
concentration of carbon monoxide (CO) in exhaled air
of at least 1 ppm. The protocol also included explora-
tory analyses of extent of smoking reduction (preceding
7 day period including abstinence days) compared to
baseline according to predefined categories (100%, 75-
99%, 50-74%, 25-49%, and < 25%).
Secondary end-points were evaluated at the week 12,
24, 36 and 48 clinical visits and included: CO-verified
smoking reduction (≥ 50%) after 12 weeks (preceding 7
day period including abstinence days), point-prevalence
estimate of smoking cessation (defined as self-reported
total abstention from cigarettes during the preceding 7
day period verified by a concentration of CO in exhaled
air of < 10 ppm at the clinical visit), estimates of contin-
ued smoking cessation (defined as self-reported total
abstention from cigarettes during the preceding 4, 12, or
24-week period verified by a concentration of CO in
exhaled air of < 10 ppm at all measurements during the
specified period), and clinical tests and biomarkers
including body weight, body mass index (BMI, defined
as weight/height
2), blood pressure, CO in exhaled air,
pulmonary function tests including forced expiratory
volume during one second (FEV1.0), forced vital capacity
(FVC), the ratio between FEV1.0 and FVC (FEV%), and
blood biomarkers (S-WBC, S-CRP, total S-cholesterol,
S-HDL, S-LDL, S-fibrinogen, and S-cotinine).
Adverse events
An adverse event (AE) was defined as any symptom,
physical sign or disease that either emerged during the
study or, if present at the baseline visit, worsened during
the study, regardless of the suspected cause of the event.
Each AE was described by the responsible trialist in
terms of duration, frequency, intensity, association with
the study medication, assessment of possible causes,
actions taken, and outcome. AEs for which an associa-
tion with the allocated study product was considered
“possible”, “probable”,o r“definite” are reported in this
paper as treatment-related. A serious AE (SAE) was
defined as any AE that was fatal or life-threatening, per-
manently disabling, resulting in unplanned or prolonged
hospitalization, or if medical interventions were required
to prevent any of the mentioned outcomes.
Study monitoring and data handling
The study was coordinated and monitored by research
personnel from an external contractor with a local office
in Belgrade (i3 Research). They were also responsible
for all data handling.
Statistical analysis
Efficacy data and intent-to-treat comparisons are
reported for all randomized participants. All statistical
methods were based on the International Conference on
Harmonization (ICH) E9 document “Statistical Princi-
ples for Clinical Trials” [20]. The statistical analyses
were performed using SAS
® v9.2 for Windows by an
external contractor (i3 Statprobe).
In order to reliably detect (p < 0.05, statistical power >
80%) a more than two-fold increase in the odds of
achieving smoking reduction at 24 weeks among the
snus versus placebo groups, and assuming a smoking
reduction rate of 15% in the placebo group versus 28%
in the snus group (corresponding to an odds ratio of
2.2), the target sample size was estimated at 156 per
treatment group for a total size of 312 study
participants.
Demographics, vital statistics and other clinical data
were summarized using summary statistics for continuous
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for categorical variables.
In the efficacy analyses participants with missing or
incomplete information, typically because of non-com-
pliance with follow-up visits, were counted as not having
achieved the end-point in question. Intent-to-treat com-
parisons of the proportion of participants achieving
smoking reduction or cessation were done using logistic
regression techniques allowing for allocated treatment,
center, age at baseline, gender, and the interaction
between treatment and center. Odds ratios were com-
puted along with the 95% confidence intervals (95% C.I.)
and two-sided p-values. The exploratory analyses of
level of smoking reduction in the two treatment groups
were done using Pearson’s chi-squared test. Changes
over time of average number of cigarettes smoked, vital
signs, and biomarker data were analyzed using mixed
effects repeated measures models. The models included
allocated treatment, center, age at baseline, gender, and
the interaction between treatment and center as fixed
effects, and used unstructured residual covariance
matrices for repeated records within subjects.
Results
Participant disposition
A total of 319 participants entered the study during Jan-
uary, 2008 through April, 2009. The 48-week study
completion rates were 56% (88/158) for the snus group,
and 63% (101/161) for the placebo group (Table 1).
Among the total of 130 participants who discontinued
prematurely, the most common reasons in both treat-
ment groups were failure to achieve the protocol defini-
tion of smoking reduction at the week 24 visit (57/130,
43.8%), withdrawal of informed consent (41/130, 31.5%),
and loss to follow-up (21/130, 16.2%).
Baseline and demographic characteristics were similar
in the snus and placebo groups (Table 2). Overall, 61%
were female. On average, participants were aged 44
years, had smoked 27 cigarettes per day during the past
year, and had made 0.6 previous quit attempts. Most of
them (81%) participated in the trial because they wanted
to quit rather than just reduce their smoking. Few parti-
cipants had previous exposure to nicotine replacement
therapy (0.9%) or other pharmaceutical cessation aids
(1.3%).
Study product usage
After the first week 97% of participants in both the snus
and placebo groups reported some daily use of their
allocated study product defined as having used at least
one sachet per day during the preceding week. This pro-
portion declined over time and was 52% after 48 weeks
in the snus group compared to 60.2% in the placebo
group (Figure 1). Among the daily users of snus the
mean amount used per day was moderate: the weekly
average ranged from 3.5 to 4.7 g per day, and was rela-
tively stable over time. Those allocated to the placebo
group had a marginally higher consumption. After the
first few weeks c. 70-80% of those who reported daily
product use preferred the small, 0.5 g sachets and the
mean number of sachets used per day in both treatment
groups was c.7-8. This number was similar irrespective
of preferred sachet size.
Cigarette consumption
The self-reported mean number of cigarettes smoked
per day (including abstinence days) decreased over time
in both the snus group and the placebo group (Figure 2,
p < 0.001). Among those allocated to snus the decrease
was slightly, but not statistically significantly more pro-
nounced compared to the placebo group during week
30-48. At the week 48 visit the mean number in the
snus group was 7.6 compared to 8.6 in the placebo
group, that is, less than one third compared to baseline
in both groups.
Cotinine and CO in exhaled air
S-cotinine decreased substantially and similarly over
time in both treatment groups (p < 0.001): at baseline
the mean concentration in the snus and placebo group
Table 1 Participant disposition
319 Randomized
Baseline: 158 (100%) Assigned to snus 161 (100%) Assigned to placebo
158 (100%) Received assigned product, included in efficacy and
safety analyses
161 (100%) Received assigned product, included in efficacy and
safety analyses
Week 1-24: 26 (16%) Discontinued study 23 (14%) Discontinued study
132 (84%) Completed protocol follow-up 138 (86%) Completed protocol follow-up
Week 24
visit:
31 (20%) Failed to achieve protocol definition of smoking
reduction
29 (18%) Failed to achieve protocol definition of smoking
reduction
101 (64%) Continued in the study 109 (68%) Continued in the study
Week 24-48: 13 (8%) Discontinued study 8 (5%) Discontinued study
88 (56%) Completed protocol follow-up 101 (63%) Completed protocol follow-up
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Characteristic Snus group (n = 158) Placebo group (n = 161)
Age, mean (SD), years 43.3 (9.9) 44.0 (10.3)
Female (%) 99 (62.7) 97 (60.2)
Weight, mean (SD), kg 76.4 (16.5) 75.8 (16.4)
Height, mean (SD), cm 170.6 (8.8) 171.9 (10.0)
BMI (kg/m
2), mean (SD) 26.1 (4.7) 25.5 (4.1)
Age at smoking initiation, mean (SD), years 19.2 (5.3) 18.8 (4.0)
Average no. of smoked cigarettes per day during last year, mean (SD) 27.6 (10.5) 25.7 (9.0)
No. of previous quit attempts, mean (SD) 0.7 (1.4) 0.6 (1.3)
Previous NRT exposure (%) 1 (0.6) 2 (1.2)
Previous exposure to other pharmaceutical smoking cessation products (%) 1 (0.6) 3 (1.9)
Intention to participate was to quit smoking (%) 132 (83.5) 127 (78.9)
FTND score, mean 6.2 6.1
SD: standard deviation, NRT: nicotine replacement therapy, FTND: Fagerström test for nicotine dependence
Figure 1 Study product usage. Proportion of participants reporting daily use (at least one sachet per day) of study product, and their mean
daily consumption, by treatment allocation and week of follow up.
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responding mean concentrations in the two groups dur-
ing follow up were 70.9 and 70.6 (12 weeks), 68.7 and
71.7 (24 weeks), 62.9 and 69.3 (36 weeks), and 66.1 and
69.1 (48 weeks). Also, CO in exhaled air decreased sta-
tistically significantly over time (p < 0.001) in both treat-
ment groups: at baseline the mean concentration was
23.5 ppm in both the snus and placebo group. The cor-
responding mean concentrations in the two groups dur-
ing follow up were 20.0 and 20.2 (12 weeks), 16.7 and
15.8 (24 weeks), 13.0 and 13.2 (36 weeks), and 11.5 and
12.1 (48 weeks). The observed decreases of cotinine and
CO in both treatment groups were thus less pronounced
than the reported decreases in number of smoked
cigarettes.
Efficacy estimates
Smoking reduction
At the week 24 visit, a total of 101 participants (63.9%)
in the snus group achieved a ≥ 50% smoking reduction
according to the protocol definition compared to 109
(67.7%) in the placebo group. This difference was not
statistically significant: the estimated odds ratio (snus
versus placebo group) was 0.81 (95% C.I.: 0.48-1.36, p =
0.42). At the week 12 visit the corresponding propor-
tions were 19.6% in the snus group (31/158) versus
12.4% in the placebo group (20/161) for an estimated
odds ratio of 1.7 (95% C.I.: 0.94-3.23, p = 0.08).
The exploratory analyses of smoking reduction
according to the predefined categories revealed that the
proportion of participants reporting more extreme
reductions in their average number of smoked cigarettes
per day (≥ 75%) at the week 24 visit was statistically sig-
nificantly higher (p < 0.01) in the snus group (15/158,
9.5%) than in the placebo group (4/161, 2.5%). At week
36 and 48 the corresponding proportions were 27/158
(17.1%) versus 17/161 (10.6%, p = 0.09), and 30/158
(19.0%) versus 21/161 (13.0%, p = 0.15).
Point-prevalence smoking abstinence
The number of participants with CO confirmed 7 day
point prevalence abstinence was higher in the snus
group compared to the placebo group at the clinical
Figure 2 Cigarette consumption. Self-reported mean number of cigarettes smoked per day during the preceding week by treatment
allocation and week of follow up.
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(snus versus placebo group) ranged from 1.9 to 3.4, but
only the estimate at 36 weeks was statistically significant
(Table 3).
Continuous smoking abstinence
The number of participants with CO confirmed smok-
ing abstinence during the preceding 4, 12, and 24 week
period was higher in the snus group compared to the
placebo group at both the week 36 and week 48 visit.
The estimated odds ratios ranged from 2.1 to 3.3, but
only the estimate for 12-week continued abstinence at
week 48 was statistically significant (Table 3)
Baseline comparisons
Vital signs
Mean blood pressure (systolic and diastolic), body
weight, BMI, and the tests for pulmonary function
(FEV1.0, FVC, FEV%) did not change appreciably over
time and there were no statistically significant differ-
ences between the two treatment groups (data not
shown).
Biomarkers
The levels of S-WBC, S-CRP, total S-Cholesterol, S-
HDL, S-LDL, and S-fibrinogen did not change appreci-
ably over time and no statistically significant differences
between the treatment groups were observed (data not
shown).
Nicotine dependence
The average FTND score among those who continued
to smoke was lower at the week 24 and 48 clinical visits
compared to baseline but there was no difference
between participants according to allocated treatment.
In the snus group the average score at baseline, after 24
weeks, and 48 weeks was 6.2, 4.2, and 4.0, respectively.
Among the placebo participants the corresponding
scores were 6.1, 4.1, and 3.6.
The reported decrease in cigarette consumption
among participants in both treatment groups contribu-
ted to the observed decreases in FTND as number of
cigarettes smoked per day is one out of the six items in
the instrument. It was beyond the scope of the current
paper to perform an exploratory analysis of the contri-
bution from the other items
Safety and tolerability
Of the 319 participants all reported having used at least
one sachet of their allocated study product and were
consequently included in the safety analysis. Using snus
was safe and generally well tolerated (Table 4). However,
treatment-related AEs were reported by 30 participants
allocated to snus (19.0%) compared to 18 in the placebo
group (11.2%, p = 0.06), but they were mostly classified
as mild and did not result in discontinuation of study
treatment. Treatment-related AEs that occurred more
frequently in the snus group typically concerned partici-
pants with symptoms related to nicotine exposure, such
as nausea (17 participants in the snus group versus 12
in the control group), increased salivation (2 versus
none), vomiting (2 versus none), and hiccups (1 versus
none). Four participants in the snus group were also
diagnosed with gingival or buccal irritation compared to
one participant from the control group. However, none
of these differences for specific AEs were statistically
significantly different between the treatment groups.
One participant in the snus group developed an SAE
(severe muscular weakness). It was classified as
Table 3 CO-verified smoking cessation outcomes
Outcome Snus, n = 158 (%) Placebo, n = 161 (%) Odds ratio
(snus vs placebo)
95% C.I. P
Point-prevalence cessation (1 week):
-week 12 2 (1.3) 0 - - -
-week 24 9 (5.7) 3 (1.9) 3.4 0.9-12.8 0.08
-week 36 15 (9.5) 6 (3.7) 2.7 1.0-7.3 0.04
-week 48 25 (15.8) 15 (9.3) 1.9 0.9-3.7 0.08
Continued cessation at week 36:
-4 weeks 13 (8.2) 6 (3.7) 2.3 0.9-6.4 0.10
-12 weeks 9 (5.7) 3 (1.9) 3.3 0.9-12.5 0.08
-24 weeks 2 (1.3) 0 - - -
Continued cessation at week 48:
-4 weeks 22 (13.9) 12 (7.5) 2.1 1.0-4.4 0.06
-12 weeks 15 (9.5) 6 (3.7) 2.7 1.0-7.3 0.04
-24 weeks 9 (5.7) 3 (1.9) 3.3 0.9-12.5 0.08
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nuation of treatment. Another participant in the snus
group discontinued using snus because of an AE (anxi-
ety) which was also classified as unrelated to use of
study product. No SAE was reported among the partici-
pants allocated to placebo.
Discussion
The current results suggested that participants allocated
to snus were more likely to quit smoking completely
than participants allocated to placebo snus. Although
the odds ratios at all time-points for the protocol-
defined estimates of smoking cessation indicated that
those allocated to snus were 1.9 to 3.4 times more likely
to quit, the findings were of borderline significance with
p-values ranging from 0.04-0.10.
The primary endpoint in the trial was a ≥ 50% smok-
ing reduction at the week 24 visit. In contrast to com-
plete cessation, the results indicated no difference
between the snus and placebo groups in terms of this
measure. The fact that the daily number of smoked
cigarettes at baseline in both treatment groups was rela-
tively high may help to explain this finding; the average
participant only needed to decrease daily consumption
to 13-14 cigarettes in order to fulfill the major protocol
criteria for this end-point. However, the proportion of
participants reporting more extreme decreases of the
average number of cigarettes smoked per day (≥ 75%
compared to baseline) was statistically significantly
higher in the snus group compared to the placebo
group at the week 24 visit (9.5% versus 2.5%, p < 0.01).
For the average participant such reduction corresponded
to daily smoking of less than c. 7 cigarettes per day. It
has been suggested that a smoker needs to decrease
consumption to low absolute levels to achieve beneficial
effects on smoking-related morbidity as less extreme
a b s o l u t er e d u c t i o n sm a yb eo f f s e tb yc o m p e n s a t o r y
smoking [21,22].
The main strength of this trial was the double-blind,
placebo-controlled design although the protocol did not
include procedures to assess the success of the blinding.
The main weakness was that the study centers had not
previously been involved in smoking cessation programs
or worked with either pharmaceutical or behavioral ces-
sation interventions. This may have contributed to the
observed relatively low overall quit rate. Another contri-
buting factor may have been that the social environment
in Serbia, with a high smoking prevalence, few smoking
restrictions, and a generally low public awareness of the
dangers of smoking, is not supportive of quit attempts
among smokers who want to stop smoking. An illustra-
tion to this was perhaps the low mean number of pre-
vious quit attempts among the participants (Table 2).
Nicotine is not harmless but it is the inhalation of
combustion products accompanying the nicotine in
tobacco smoke that explains most of the excess morbid-
ity and mortality experienced by smokers. These cir-
cumstances formed part of the rationale for the study
design which included usage of study product ad libi-
tum over the entire 48 week study period with no pre-
scribed tapering of product use after a specified time
point. The aims of the trial thus did not include treating
the participants’ nicotine dependence. Clinical experi-
ence from Scandinavia indicates that smokers who use
snus as a smoking cessation aid typically do not switch
abruptly from cigarettes to snus. The transition period
of dual daily use can last from weeks to months, so in
this study there was a grace period of 24 weeks before
the participants were actively instructed to completely
refrain from smoking. On the other hand, a long “grace
period” before a target quit date could theoretically lead
to dissipation of the motivation to quit among some
smokers. Smokers who have successfully quit by switch-
ing to snus typically do not abruptly stop using snus
after a few weeks or months. In fact, a substantial pro-
portion of smokers who have switched to snus become
long term users [23]. The same appears to apply also to
pharmaceutical nicotine; several studies have indicated
that a proportion of ex-smokers who quit using NRT
continue to use such products long-term [24-26].
Beneficial effects from smoking reduction or cessation
on vital signs (e.g. blood pressure and pulmonary func-
tion) and biomarker levels (e.g. CRP, fibrinogen, and
blood lipids) are mainly observed among those who quit
completely and typically take several weeks to months
to emerge. The overall low complete cessation rates in
this study may have contributed to the fact that we
could not detect any statistically significant overall dif-
ferences between the treatment groups in terms of such
measures, despite the difference in number of quitters
Table 4 Summary of adverse events (AE)
Snus group, n = 158 (%) Placebo group, n = 161 (%)
Any AE 42 (26.6) 26 (16.1)
SAE 1 (0.6) 0
AE leading to discontinuation of study treatment 2 (1.3) 0
Treatment-related AE 30 (19.0) 18 (11.2)
SAE: serious adverse event, Treatment-related: relation to allocated study treatment considered by the trialist to be possible, probable, or definite,
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Page 9 of 11in favor of the snus group. Any differences that may
have occurred as a result of this difference were prob-
ably obscured by the results for the large number of
non-quitters. The generally small number of quitters
also precluded meaningful exploratory analyses accord-
ing to quitting behavior.
Unassisted cessation remains the most common
method by which smokers quit, but in Scandinavia snus
is the most frequently reported method among those
who use some form of cessation aid [27,28]. Also, snus
appears to be associated with a higher long-term success
rate compared to pharmaceutical nicotine [28]. Possible
explanations include the more rapid nicotine delivery
from snus [17], and the fact that snus is typically used
more long term [23].
Conclusions
Snus use is traditional in Sweden, particularly among
males. It has been hypothesized that cultural factors
may make snus unacceptable or ineffective as a smoking
cessation aid outside of Scandinavia [29]. This trial
demonstrated that Swedish snus was acceptable and
could promote smoking cessation also among smokers
in Serbia, that is, in a cultural setting without traditional
use of any form of oral tobacco.
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